| scholarly article | Q13442814 |
| P2093 | author name string | Mehran M Sadeghi | |
| Albert J Sinusas | |||
| Scott Edwards | |||
| Jeffrey R Bender | |||
| Jiasheng Zhang | |||
| Ali Kooshkabadi | |||
| Leila Esmailzadeh | |||
| Thomas D Harris | |||
| Padmaja Yalamanchili | |||
| Amir A Gharaei | |||
| Barry L Zaret | |||
| Hooman Rastegar Fassaei | |||
| Svetlana Krassilnikova | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microvasculature remodeling | Q6840464 |
| P304 | page(s) | 84-90 | |
| P577 | publication date | 2004-06-21 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo | |
| P478 | volume | 110 |
| Q37085672 | Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis |
| Q37529871 | Applications for site-directed molecular imaging agents coupled with drug delivery potential |
| Q36390068 | Atherosclerosis imaging on the molecular level |
| Q35607634 | Atherosclerosis plaque heterogeneity and response to therapy detected by in vivo molecular imaging of matrix metalloproteinase activation. |
| Q47881730 | Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases |
| Q41926512 | Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. |
| Q39767081 | Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). |
| Q34662862 | ESDN is a marker of vascular remodeling and regulator of cell proliferation in graft arteriosclerosis. |
| Q37286476 | Effect of Thyrotropin on Osteopontin, Integrin αvβ3, and VCAM-1 in the Endothelium via Activation of Akt. |
| Q37709428 | Emergence of molecular imaging of aortic aneurysm: implications for risk stratification and management |
| Q36759502 | Emerging nanomedicine opportunities with perfluorocarbon nanoparticles |
| Q37245368 | High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model |
| Q34412168 | High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis |
| Q61727635 | Imaging aortic wall inflammation |
| Q30435383 | Imaging atherosclerosis and vulnerable plaque |
| Q37407240 | Imaging of the unstable plaque: how far have we got? |
| Q33851309 | Integrin αvβ3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy |
| Q35586045 | Integrin-targeted imaging of inflammation in vascular remodeling |
| Q37222177 | Intracellular and extracellular targets of molecular imaging in the myocardium |
| Q37306731 | Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury |
| Q36182417 | MR molecular imaging of aortic angiogenesis. |
| Q34420376 | Matrix Metalloproteinase Activation Predicts Amelioration of Remodeling After Dietary Modification in Injured Arteries |
| Q36804990 | Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits |
| Q26747500 | Molecular Imaging of Angiogenesis and Vascular Remodeling in Cardiovascular Pathology |
| Q36700579 | Molecular cardiovascular imaging using scintigraphic methods |
| Q30442045 | Molecular imaging in cardiovascular disease: Which methods, which diseases? |
| Q30485880 | Molecular imaging of activated matrix metalloproteinases in vascular remodeling |
| Q34033191 | Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrin-targeted nanoparticles |
| Q36095916 | Molecular imaging of coronary atherosclerosis and myocardial infarction: considerations for the bench and perspectives for the clinic |
| Q30479243 | Molecular imaging of inflammation and intraplaque vasa vasorum: a step forward to identification of vulnerable plaques? |
| Q30495622 | Molecular imaging of matrix metalloproteinase activation to predict murine aneurysm expansion in vivo. |
| Q40361537 | Molecular imaging of vulnerable atherosclerotic plaques |
| Q37177648 | Molecular imaging will replace perfusion imaging: The impossible dream |
| Q30438207 | Multimodality cardiovascular molecular imaging, Part II |
| Q37983684 | Multimodality imaging in interventional cardiology |
| Q37003713 | Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging |
| Q34159603 | Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice |
| Q53867884 | Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and the metabolic syndrome. |
| Q37761310 | Non-invasive Monitoring of Angiogenesis in Cardiology |
| Q34380380 | Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction |
| Q26772106 | Novel Molecular Imaging Approaches to Abdominal Aortic Aneurysm Risk Stratification |
| Q35641937 | PET Imaging of Integrin Positive Tumors Using F Labeled Knottin Peptides |
| Q37638149 | PET and SPECT in cardiovascular molecular imaging |
| Q37438144 | Pre-clinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: an overview |
| Q36355372 | Quantitative Longitudinal Imaging of Vascular Inflammation and Treatment by Ezetimibe in apoE Mice by FMT Using New Optical Imaging Biomarkers of Cathepsin Activity and α(v)β(3) Integrin |
| Q37085665 | Radiolabeled arginine-glycine-aspartic acid peptides to image angiogenesis in swine model of hibernating myocardium |
| Q33650693 | Role of molecular imaging with positron emission tomographic in aortic aneurysms |
| Q28066121 | SPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular disease |
| Q48566449 | Second Annual Mario S. Verani, MD, Memorial Lecture: Nuclear cardiology, the next 10 years |
| Q35590573 | Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma. |
| Q48884224 | Targeted imaging of hypoxia-induced integrin activation in myocardium early after infarction |
| Q34037800 | Targeting of alpha(nu)beta(3)-integrins expressed on tumor tissue and neovasculature using fluorescent small molecules and nanoparticles |
| Q46535633 | The atherosclerotic plaque: a healthy challenge to the limits of nuclear imaging |
| Q36496252 | The pathobiology of the vessel wall: implications for imaging |
| Q30474759 | Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions |
| Q37039058 | Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model |
| Q37384099 | Transmembrane protein ESDN promotes endothelial VEGF signaling and regulates angiogenesis. |
| Q34452451 | Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. |
Search more.